AdAlta and XL-protein announce collaboration to develop a long acting version of its lead fibrosis drug candidate AD-114 using PASylation® Technology
Melbourne, Australia and FREISING, Germany, 7 November 2016:…
Akari Therapeutics Plc and XL-protein GmbH Sign License Agreement to Develop a Long Acting Version of Coversin Using PASylation® Technology
NEW YORK, LONDON, and FREISING, Germany, April 14, 2016 - Akari…
DNX Biopharmaceuticals and XL-protein Enter into a Shareholder Agreement to Develop and Commercialize Novel Long Acting Biopharmaceuticals.
Irvine, California, and Freising, Germany, February 1, 2016
On…